'Extremely important outcome for Alzheimer's patients' following Synaptogenix trial

By Liza Laws

- Last updated on GMT

© Getty Images
© Getty Images

Related tags Alzheimer's disease Clinical trial Synaptogenix Inc. neurodegenerative diseases phase 2

Patients with severe Alzheimer's Disease (AD) showed no cognitive decline throughout a ten-month trial while being treated with Bryostatin-1.

Emerging biotech, Synaptogenix Inc., develops therapeutics for neurodegenerative disorders recently announced a peer-reviewed publication of ‘statistically significant’ integration of secondary and exploratory endpoint data from its previously completed phase 2 trial of Bryostatin-1 for AD.

The paper​, ‘Advanced Alzheimer's Disease (AD) Patients Show Safe, Significant, and Persistent Benefit in 6 Month Bryostatin Trial,’ appears in the Journal of Alzheimer's Disease.

Conclusions published include analyses of the trial’s severe cohort that indicate Bryostatin-treated MMSE 10-14 patients showed no significant cognitive decline throughout the 10-month trial, compared with placebo patients' decline of -12.8 SIB points.

Synaptogenix said the paper discusses persistence in the data, stating, ‘the prolonged absence of any significant cognitive decline in Bryostatin-treated patients vs. placebo patients – even 16 weeks after the final dose of Bryostatin – suggests a long-lasting positive change in the treated patients' brains.’

Alan Tuchman , chief executive officer of Synaptogenix, said, "There is a huge unmet need in the AD population for drugs oriented specifically to advanced and severe patients. Approved drugs do exist for slowing decline in non-demented, Mild Cognitive Impairment (MCI) patients and possible early AD patients, but Bryostatin-1-treated Severe Cohort patients, in contrast, showed no significant cognitive decline across a 10-month span in our study.

“We believe that Bryostatin-1 for later-stage patients would be complementary to the early-stage AD drugs in providing a full range of treatment options for the more than six million Americans living with Alzheimer's disease.”

Synaptogenix's six-month phase 2 clinical trial was a randomized, double-blind, placebo-controlled study comparing Bryostatin-1 to placebo for long-term efficacy in the treatment of advanced and severe AD in the absence of memantine.

While moderate cohort patients showed no significant benefit, the data demonstrates that Bryostatin-1​-treated patients in the severe cohort showed statistically significant improvement of cognitive performance over placebo patients for weeks 13 through to 42, with the last dose administered at week 26.

The study was conducted with financial support from the National Institute on Aging (NIA) and the National Cancer Institute (NCI), both part of the NIH.

Daniel Alkon, president, and chief scientific officer, added, “We appreciate the acknowledgement from such an esteemed independent Alzheimer's journal. Persistence of real benefit at least 16 weeks beyond the final Bryostatin dosing is an extremely important outcome for Alzheimer's patients in the more advanced stages of the disease.”

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us


View more